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TopBP1 serves as an activator of the
ATR-ATRIP complex in response to the
presence of incompletely replicated or damaged
DNA.  This process involves binding of ATR to
the ATR-activating domain of TopBP1, which
is located between BRCT domains VI and VII.
TopBP1 displays increased binding to ATR-
ATRIP in Xenopus  egg extracts containing
checkpoint-inducing DNA templates.  We show
that an N-terminal region of TopBP1
containing BRCT repeats I-II is essential for
this checkpoint-stimulated binding of TopBP1
to ATR-ATRIP.  The BRCT I-II region of
TopBP1 also binds specifically to the Rad9-
Hus1-Rad1 (9-1-1) complex in Xenopus egg
extracts.  This binding occurs via the C-
terminal domain of Rad9 and depends upon
phosphorylation of its Ser-373 residue.  Egg
extracts containing either a mutant of TopBP1
lacking the BRCT I-II repeats or a mutant of
Rad9 with an alanine substitution at Ser-373
are defective in checkpoint regulation.
Furthermore, an isolated C-terminal fragment
from Rad9 is an effective inhibitor of
checkpoint signaling in egg extracts.  These
findings suggest that interaction of the 9-1-1
complex with the BRCT I-II region of TopBP1
is necessary for binding of ATR-ATRIP to the
ATR-activating domain of TopBP1 and the
ensuing activation of ATR.
Eukaryotic cells possess checkpoint
regulatory mechanisms that are essential for
safeguarding of the genome (1-3).  Components of
these biochemical systems probe chromosomes for
the presence of damaged or partially replicated
DNA.  ATM2 and ATR, which are both
phosphoinositide kinase-related protein kinases
(PIKKs), operate near the apex of checkpoint
pathways (1).  ATM is involved mainly in the
detection of double-stranded DNA breaks (DSBs)
(4).  ATR has a discrete role in the detection of
stalled DNA replication forks, but it also functions
in DSB-triggered responses (1,4,5).  A critical
function of ATR involves activation of the
downstream checkpoint effector kinase Chk1.  In
turn, Chk1 prohibits cell cycle progression by
phosphorylating downstream cell cycle control
proteins such as Cdc25 and Wee1 as long as
damaged or incompletely replicated DNA is
present in the cell (6).
The ATR-dependent activation of Chk1 is
an elaborate process that involves numerous
additional factors (3,5,7).  ATR itself possesses a
tightly bound and indispensable subunit called
ATRIP (8).  Our laboratory has demonstrated that
a protein known as TopBP1 functions as a direct
activator of ATR-ATRIP (9).  Once ATR-ATRIP
becomes activated by TopBP1, it requires the
assistance of the mediator protein Claspin in order
to carry out the final activating phosphorylations
of Chk1 (10-13).  Other factors that are important
in the pathway leading to the activation of Chk1
include checkpoint clamp loader and clamp
complexes (3).  In particular, a clamp loader
consisting of Rad17 and the four small replication
factor C (RFC) subunits catalyzes deposition of a
trimeric checkpoint clamp onto checkpoint-
triggering locations in chromosomes.  This clamp,
which is composed of Rad9, Hus1, and Rad1, is
commonly referred to as the 9-1-1 complex (14).
It is thought that this complex is loaded onto
recessed DNA ends, which would be present at
both stalled DNA replication forks and DSBs that
have undergone resection (15-19).
We have been investigating how the
action of TopBP1 as an ATR-activating protein
might be regulated during checkpoint responses.
Recently, our laboratory reported that TopBP1
displays increased binding to ATR-ATRIP in the
presence of checkpoint-triggering DNA templates
in Xenopus egg extracts (20).  Here we show that
this regulated binding involves an N-terminal
domain of TopBP1 containing its first two BRCT
repeats.  This region was not previously known to
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2be important for the checkpoint-regulatory
function of TopBP1 (21,22).  This segment does
not bind directly to ATR-ATRIP, but does interact
well with the 9-1-1 complex via the C-terminal
region of the Rad9 protein.  This interaction is
necessary for normal activation of Chk1 in
Xenopus egg extracts.  Thus, interaction of Rad9
with an essential region of the ATR-activating
protein TopBP1 is critical for the initiation of
checkpoint signaling.
EXPERIMENTAL PROCEDURES
Xenopus egg extracts—Extracts from
Xenopus egg were prepared as described
previously (23).  The DNA replication checkpoint
was induced by addition of aphidicolin (50 µg/ml)
to interphase egg extracts containing
demembranated sperm nuclei (4,000/µl) and
cycloheximide (100 µg/ml).  Alternatively,
checkpoint responses were triggered by addition of
50 µg/ml (dA)70-(dT)70 to egg extracts
supplemented with 3 µM tautomycin (10).
Methods for isolation of total nuclear and
chromatin fractions were described previously
(24).
Antibodies and
immunodepletion—Antibodies against Xchk1,
Xhus1, Xmcm7, Claspin, phospho-Ser-864 of
Claspin, Xatr, and XtopBP1 were previously
described (9,10,23-25).  Antisera against Xrad9
and Xrad1 were kindly provided by Dr. Howard
Lindsay (University of Lancaster, United
Kingdom).  Anti-GST and anti-phospho-Ser-344
of Xchk1 antibodies were purchased from Santa
Cruz Biotechnology and Cell Signaling
Technology, respectively.  Control IgG was
obtained from Zymed.  For immunodepletion of
the 9-1-1 complex, affinity-purified anti-Xhus1
antibodies (150 µg total) were bound to
recombinant protein A-Sepharose (Pharmacia) and
incubated with egg extract (100 µl) in three
successive rounds.  XtopBP1 was immunodepleted
by published methods (9).
Recombinant proteins—DNA constructs
encoding various deletion mutants of HF-XtopBP1
lacking the indicated residues (ΔI-II, 106-282;
ΔIII, 360-428; ΔIV-V, 588-710; ΔVI, 760-1014;
ΔAAD, 993-1196; and ΔVII-VIII, 1227-1485)
were produced using the QuikChange kit
(Stratagene) with pFastBac-HF-XtopBP1 as
template (20).  HF-XtopBP1 contains both
hemagglutinin (HA) and His6 tags at the N-
terminal end and a FLAG tag at the C-terminal
end.   In the case of XtopBP1 fragments
containing the N-terminal region (Δ760-1485), C-
terminal region (Δ1-757), and BRCT domains I-II
(Δ360-1485) and III-VI (Δ2-312 and Δ1006-1485),
sequences encoding the indicated amino acids
were removed by PCR-based methods.  All
recombinant versions of XtopBP1 were designed
to contain the region with its putative nuclear
localization sequence (amino acids 1495-1500),
and were observed to enter the nucleus normally
(data not shown).  The sequence encoding Xrad9
was subcloned into the pFastBac-HTb vector to
generate the His6-Xrad9 construct.  Serine 393 of
Xrad9 was changed into alanine (Xrad9-S393A)
with the QuikChange kit.  Recombinant
baculoviruses were produced with Bac-to-Bac
system (Invitrogen).  Expressed proteins were
purified with nickel agarose beads (10).  For
preparation of recombinant Xenopus 9-1-1
complex, baculoviruses encoding untagged Xhus1
and Xrad1 (kindly provided by Dr. Karlene
Cimprich, Stanford University) and His6-Xrad9
were used to coinfect Sf9 insect cells.  The
complexes were purified as described (26) and
analyzed by SDS-PAGE and immunoblotting.
Sequences encoding various segments from the C-
terminal region of Xrad9 were amplified by PCR
and inserted into the pGEX-4T3 vector
(Pharmacia).  Unless indicated otherwise, the
construct containing residues 258-377 is referred
to as GST-Xrad9C.  GST fusion proteins were
expressed in Escherichia coli BL21 pLysS cells
and purified with glutathione agarose beads.  For
inhibition of the phosphorylation of Xchk1 in egg
extracts, these peptides were added up to a final
concentration of 0.1 mg/ml.  35S-Labeled Xchk1
was synthesized in vitro with TnT reticulocyte
lysate system (Promega).
Protein binding assays—HF-XtopBP1
proteins (2µg) were incubated in 100 µl of
interphase egg extract for 90 min and recovered
with anti-FLAG antibody beads (Sigma).  In some
cases, anti-FLAG antibodies were bound to
protein G magnetic beads (Dynal Biotech).  For
GST-Xrad9 fragments, proteins (5 µg each) were
incubated in 100 µl of interphase egg extract for
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390 min and recovered with glutathione beads as
described previously (10).  Treatments with λ
protein phosphatase (20 U/µl; New England
Biolabs) were carried out on GST-Xrad9C bound
to glutathione agarose beads for 30 min at room
temperature in the buffer provided by the
manufacturer.
Phosphopeptide mapping—Wild-type and
S373A GST-Xrad9C were incubated in egg
extracts supplemented with [γ-32P]ATP for 90 min
and purified as described above.  Labeled proteins
were excised from SDS gels and digested with
trypsin.  Phosphopeptide mapping was carried out
as before (27).
RESULTS
XtopBP1 Associates with the C-Terminal
Domain of Xrad9 in Frog Egg Extracts—The C-
terminal domain of Rad9 is important for
checkpoint signaling in yeast and vertebrates
(26,28-30).  In order to examine a potential
functional relationship between this region of
Rad9 and TopBP1 in Xenopus egg extracts, we
prepared a GST fusion protein containing the C-
terminal 120 amino acids of Xenopus Rad9
(Xrad9) (residues 258-377).  We incubated this
fusion protein (hereafter referred to as GST-
Xrad9C) in egg extracts, subsequently recovered
the protein with glutathione agarose beads, and
performed immunoblotting with antibodies against
Xenopus TopBP1 (XtopBP1).  As shown in Fig.
1A, we could readily detect binding of endogenous
XtopBP1 from egg extracts to exogenously added
GST-Xrad9C.  There was no binding of XtopBP1
to glutathione beads in extracts without added
GST-Xrad9C.  In these experiments, we observed
a large upward mobility shift of GST-Xrad9C in
SDS gels as a result of incubation in egg extracts.
This shift appears to represent phosphorylation,
because it can be abolished by treatment with λ
protein phosphatase.  Furthermore, this
phosphatase treatment caused dissociation of
XtopBP1 that had originally bound to GST-
Xrad9C in egg extracts.  This observation suggests
that the interaction between XtopBP1 and GST-
Xrad9C depends upon phosphorylation.
In order to examine which portion of
Xrad9C is important for binding to XtopBP1, we
prepared a variety of deletion mutants.  As
depicted in Fig. 1B, removal of up to 80 amino
acids from the N-terminal end of the fragment did
not affect binding significantly.  However,
removal of 20 additional residues (to yield the
358-377 fragment) did completely abrogate
interaction with XtopBP1.  Moreover, deletion of
the last 20 amino acids from the opposite C-
terminal end of the 258-377 fragment also
eliminated binding to XtopBP1 (Fig. 1C and D).
Taken together, these results indicate that the last
20 amino acids of Xrad9 are necessary for binding
of XtopBP1 in egg extracts, but that a somewhat
larger fragment containing up to 40 C-terminal
amino acids is sufficient.  These findings are
consistent with studies in human cells (31).
The C-terminal domain of Rad9 is highly
phosphorylated in yeast and vertebrates (28-30).
Within the last twenty amino acids of human
Rad9, S387 is constitutively phosphorylated
during the cell cycle in tissue culture cells and is
required for binding of TopBP1 (29).
Phosphorylation of human Rad9 on S387 does not
require the presence of a checkpoint-inducing
DNA lesion.  This residue is highly conserved in
vertebrates and corresponds to S373 in Xrad9 (see
Fig. 1C).  In this region of fission yeast Rad9, both
T412 and S423 undergo phosphorylation (30).
Phosphorylation of T412 has been implicated in
the binding of Rad9 to Cut5 in fission yeast.  In
order to test whether phosphorylation of S373 is
necessary for binding of Xrad9 to XtopBP1 in egg
extracts, we mutated this residue to alanine in the
context of the GST-Xrad9C protein.  The resulting
S373A mutant had virtually no ability to interact
with XtopBP1 (Fig. 1D).  We verified by tryptic
phosphopeptide mapping that S373 of GST-
Xrad9C (containing residues 258-377) undergoes
phosphorylation in egg extracts (Fig. 1E).
Role of S373 from Xrad9 in Checkpoint
Regulation—We proceeded to assess whether
S373 of Xrad9 is involved in checkpoint signaling
in egg extracts.  For this purpose, we
immunodepleted the endogenous 9-1-1 complex
from egg extracts with anti-Xhus1 antibodies and
replaced it with recombinant 9-1-1 complexes
containing either wild-type or S373A Xrad9 (Fig.
2A and B).  In parallel, we prepared mock-depleted
extracts with control antibodies.  We added
aphidicolin and demembranated Xenopus sperm
nuclei to the extracts in order to create chromatin
with DNA replication blockages.  Finally, we
monitored activation of the DNA replication
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4checkpoint by observing phosphorylation of 35S-
Xchk1 in nuclear fractions from the extracts.  As
shown in Fig. 2C, removal of the 9-1-1 complex
from egg extracts resulted in a significant
reduction of the aphidicolin-induced
phosphorylation of Xchk1, consistent with
previous results (26,32).  Phosphorylation could be
restored by the addition of recombinant wild-type
9-1-1 complex, but not a mutant complex with the
S373A Xrad9 subunit.  Therefore, S373 of Xrad9
appears to be functionally important for
checkpoint signaling.
Xrad9 Interacts with the BRCT I-II Region
of XtopBP1—Next, we examined which portion of
XtopBP1 is necessary for interaction with Xrad9.
For this question, we prepared deletion mutants of
recombinant, full-length XtopBP1 (HF-XtopBP1)
lacking certain BRCT domains (see Fig. 3A).  In
particular, we removed regions that contain BRCT
domains I-II, III, IV-V, VI, and VII-VIII.  In
addition, we prepared a deletion mutant of
XtopBP1 that lacks its ATR-activating domain
(AAD) (9).  We incubated wild-type HF-XtopBP1
and the various deletion mutants in Xenopus egg
extracts, recovered the proteins with anti-FLAG
antibody beads, and then performed
immunoblotting with anti-Xrad9 antibodies.
Typically, all of the recombinant XtopBP1
proteins with the exception of the one lacking
BRCT domains I-II could associate with
endogenous Xrad9 in egg extracts (Fig. 3B).
Likewise, we observed the same binding pattern
for endogenous Xhus1, another component of the
9-1-1 complex.  Interestingly, we could also detect
binding of endogenous Xrad17 (the large subunit
of the Xenopus Rad17-RFC clamp loader) to all of
the constructs that bound the 9-1-1 components.
In parallel, we also asked whether the isolated
GST-Xrad9C fragment displayed similar binding
properties.  We observed that the C-terminal
domain of Xrad9 could not associate with the ΔI-II
mutant of XtopBP1, whereas it bound readily to
wild-type, ΔAAD, and ΔIII versions of XtopBP1
under the same conditions (Fig. 3C).
We also investigated which regions of
XtopBP1 are sufficient for binding of Xrad9.  For
these experiments, we used FLAG-tagged
fragments of XtopBP1 containing approximately
its N-terminal and C-terminal halves.  In addition,
we prepared smaller recombinant fragments
containing BRCT domains I-II or III-VI.
Consistent with the results described above, the N-
terminal domain of XtopBP1 bound well to
endogenous Xrad9 and Xhus1, whereas there was
no binding of the C-terminal domain (Fig. 3D).
Furthermore, a fragment of XtopBP1 containing
BRCT domains I-II, but not one comprised of
domains III-VI, could associate with endogenous
Xrad9 and Xhus1 from egg extracts.  Finally, in
reciprocal binding experiments, we found that
GST-Xrad9C could pull-down both the N-terminal
half of XtopBP1 and the BRCT I-II fragment, but
not the C-terminal half of the protein or the BRCT
III-VI fragment (Fig. 3E).  Taken together, these
results indicate that the BRCT I-II region of
XtopBP1 is both necessary and sufficient for
binding to the C-terminal domain of Xrad9.
The BRCT I-II Domain of XtopBP1 is
Essential for Checkpoint Signaling in Egg
Extracts—We turned to the issue of whether the
BRCT I-II domain of XtopBP1 is required for
checkpoint signaling.  In order to address this
question, we immunodepleted endogenous
XtopBP1 from egg extracts with anti-XtopBP1
antibodies and replaced it with either wild-type,
ΔAAD, or ΔI-II versions of HF-XtopBP1 (Fig.
4A).  Next, we added sperm chromatin and
aphidicolin to the extracts, and then examined
phosphorylation of Xchk1 in nuclear fractions
(Fig. 4B).  As expected, there was no
phosphorylation of Xchk1 in XtopBP1-depleted
extracts (9,21,22,33).  Consistent with previous
reports, we could restore this phosphorylation by
adding back wild-type full-length HF-XtopBP1
(9,21,22).  However, we could not rescue this
defect with ΔAAD mutant of HF-XtopBP1, which
reflects the fact that the AAD is required for
activation of ATR.  Significantly, we found that
the ΔI-II mutant was also unable to support
phosphorylation of Xchk1 even though it contains
an intact AAD.  This observation suggests that the
BRCT I-II region somehow regulates the function
of the AAD.  In order to corroborate this finding
further, we used the model DNA template (dA)70-
(dT)70.  This double-stranded template, which
induces a strong XtopBP1-activation of Xatr,
elicits a robust phosphorylation of Xchk1 (10,12).
By contrast, a single-stranded template such as
(dA)70 does not induce activation of Xatr.  The
activation of Xchk1 in the presence of (dA)70-
(dT)70 does not require any DNA replication in
egg extracts.  We prepared XtopBP1-depleted
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5extracts, supplemented them with either wild-type
or ΔI-II XtopBP1, and finally added either (dA)70
or (dA)70-(dT)70.  As shown in Fig. 4C, the extract
containing wild-type XtopBP1 displayed robust
phosphorylation of Xchk1 in the presence of
(dA)70-(dT)70 but not (dA)70.  By contrast, addition
of (dA)70-(dT)70 did not induce phosphorylation of
Xchk1 in the extract containing the ΔI-II mutant of
XtopBP1.  Taken together, these results indicate
that BRCT I-II region of XtopBP1 is essential for
the Xatr-dependent activation of Xchk1 in
response to a number of different checkpoint-
inducing DNA templates.
The BRCT I-II Region Regulates
Association of XtopBP1 with Xatr-Xatrip—In
order to investigate the mechanism by which the
BRCT I-II region of XtopBP1 participates in
checkpoint regulation, we explored the Xatr-
binding properties of the ΔI-II mutant.  Our
laboratory recently reported that Xatr-Xatrip
displays increased binding to XtopBP1 upon
addition of the checkpoint-inducing DNA template
(dA)70-(dT)70 to egg extracts (20).  To investigate
what regions of XtopBP1 contribute to this
regulation, we incubated wild-type or ΔI-II
versions of HF-XtopBP1 in egg extracts
containing either (dA)70 or (dA)70-(dT)70 (Fig. 5A).
There was basal binding of wild-type HF-
XtopBP1 to Xatr in the presence of (dA)70.  This
binding increased in extracts containing (dA)70-
(dT)70.  However, we observed that the ΔI-II
mutant of XtopBP1 did not bind detectably to Xatr
in extracts containing either (dA)70 or (dA)70-
(dT)70.
To investigate the generality of these
findings, we also used extracts containing
aphidicolin-induced DNA replication blocks in
chromatin.  As depicted in Fig. 5B, we could
likewise observe good binding of HF-XtopBP1 to
Xatr in nuclei from aphidicolin-treated extracts.
However, there was only very weak binding of the
ΔI-II mutant of XtopBP1 to Xatr under the same
conditions.  Taken together, these results indicate
that the checkpoint-induced binding of XtopBP1
to Xatr depends upon the BRCT I-II region of
XtopBP1.  This observation is intriguing because
we showed previously that the AAD of XtopBP1
associates with Xatr-Xatrip (9).  Furthermore, we
have been unable to observe binding of Xatr-
Xatrip to the isolated BRCT I-II domain of
XtopBP1 (data not shown).  The implication is
that the BRCT I-II region regulates the ability of a
distinct region in the protein (namely, the AAD) to
associate with Xatr-Xatrip.
The Isolated C-Terminal Domain of Xrad9
Acts as a Dominant-negative Inhibitor of
Checkpoint Signaling in Egg Extracts—As another
means to assess the importance of the interaction
between Xrad9 and XtopBP1, we examined
whether the GST-Xrad9C fragment could act as an
inhibitor of checkpoint signaling in the egg-extract
system.  For this purpose, we added either wild-
type or S373A versions of GST-Xrad9C to
aphidicolin-treated extracts and subsequently
examined phosphorylation of Xchk1.  In these
experiments, we monitored phosphorylation of
Xchk1 by immunoblotting with antibodies specific
for phosphorylated S344 of Xchk1 (34,35).
Significantly, the wild-type version of GST-
Xrad9C caused a marked reduction in the
phosphorylation of Xchk1 on S344 (Fig. 6A).  In
addition, this fragment also caused a large
decrease in the phosphorylation of Claspin on
S864, a checkpoint-regulated phosphorylation that
is necessary for binding of Claspin to Xchk1 (36).
By contrast, the S373A mutant of GST-Xrad9C
had little, if any, effect on the phosphorylation of
either Xchk1 or Claspin.  The GST-Xrad9C
fragment had no effect on chromosomal DNA
replication in egg extracts (data not shown).  In
order to corroborate these findings further, we
used the model DNA template (dA)70-(dT)70 to
induce a checkpoint response.  Consistent with the
results described above, wild-type but not S373A
GST-Xrad9C also abolished the phosphorylation
of Xchk1 in response to (dA)70-(dT)70 (Fig. 6B).
In order to explore how GST-Xrad9C
interferes with phosphorylation of Xchk1, we
analyzed whether this fragment might affect
binding of checkpoint proteins to chromatin.  We
observed that the wild-type GST-Xrad9C fragment
caused a significant reduction in the binding of
endogenous XtopBP1 to aphidicolin-treated
chromatin (Fig. 6C).  Conversely, the S373A
mutant of GST-Xrad9C had no effect on the
chromatin-binding properties of XtopBP1.  On the
other hand, neither the wild-type nor S373A forms
of GST-Xrad9C appeared to have an effect on
interaction of Xatr with aphidicolin-treated
chromatin.  These findings suggest that GST-
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6Xrad9C perturbs the interaction of XtopBP1 with
Xatr-Xatrip at stalled replication forks.
DISCUSSION
In this report, we have explored how the
ability of TopBP1 to activate ATR is regulated
during checkpoint responses.  The binding of
XtopBP1 to the Xatr-Xatrip complex in Xenopus
egg extracts increases in the presence of a
checkpoint-triggering DNA template (20).  We
have found that an N-terminal region of XtopBP1
encompassing BRCT repeats I-II is critical for this
regulated binding.  This segment of XtopBP1 does
not associate directly with Xatr-Xatrip.  Instead,
this region is necessary for Xatr-Xatrip to dock
with the AAD of XtopBP1, which is situated near
the other end of the protein between BRCT
domains VI and VII.  This process is essential for
checkpoint signaling because egg extracts
containing a mutant of XtopBP1 lacking the
BRCT I-II region are completely defective in
carrying out the activation of Xchk1.
In exploring the mechanism by which the
BRCT I-II region contributes to the checkpoint-
regulatory function of XtopBP1, we examined
potential binding partners of XtopBP1.  Genetic
and biochemical studies in a number of different
organisms have indicated that the 9-1-1 complex
and its equivalents interact with TopBP1 and its
homologs (29-31,37,38).  This binding involves C-
terminal region of the Rad9 protein.  We have
found that XtopBP1 interacts strongly with the C-
terminal domain of Xrad9.  The BRCT I-II region
of XtopBP1 is both necessary and sufficient for
binding to the C-terminal section of Xrad9.  About
20-40 amino acids from the extreme C-terminal
end of Xrad9 are involved in this interaction.
Furthermore, this binding requires
phosphorylation of Xrad9 on S373.  This
interaction is functionally important for
checkpoint regulation.  For example, a mutant 9-1-
1 complex containing an S373A version of the
Xrad9 subunit is compromised in checkpoint
signaling.  Moreover, a GST fusion protein
containing the C-terminal region of Xrad9 (GST-
Xrad9C) is an effective dominant-negative
inhibitor of the activation of Xchk1 in egg
extracts.  By contrast, the corresponding S373A
mutant of GST-Xrad9C has no effect on the
activation of Xchk1.  Altogether, the results
indicate that interaction of S373-phosphorylated
Xrad9 with the BRCT I-II region of XtopBP1 is
essential for checkpoint control.
Fission yeast Cut5 and budding yeast
Dpb11, the relatives of TopBP1 in these
organisms, interact with Rad9 and its budding
yeast homologue Ddc1, respectively, through C-
terminal regions containing BRCT repeats III-IV
(30,37).  This finding apparently contrasts with
our observation that the N-terminal BRCT I-II
region of XtopBP1 associates with Xrad9.
However, the yeast proteins are considerably
smaller than vertebrate TopBP1 and possess only
four BRCT repeats, as opposed to eight in the
vertebrate proteins.  Furthermore, the AAD is not
obviously conserved in fission yeast Cut5 and
budding yeast Dpb11.  Indeed, the AAD appears
to be strongly conserved only in vertebrates.  In
general, it appears that the yeast and vertebrate
versions of TopBP1 are similar in that they are
involved in both DNA replication and checkpoint
control (7).  Nonetheless, there are substantial
structural differences between the yeast and
vertebrate forms of these proteins.
In a previous study, Mäkiniemi and
coworkers (38) found in yeast two-hybrid
experiments that human TopBP1 interacts with
human Rad9 through BRCT repeats IV-V.
However, these authors did not carry out studies in
human cells or biochemical experiments to
establish that BRCT IV-V is either necessary or
sufficient for binding of Rad9.  Furthermore, these
investigators did not examine whether this region
is involved in checkpoint regulation.  Overall, we
believe that we have provided convincing
evidence that the BRCT I-II region of XtopBP1
mediates a functionally important interaction with
Xrad9 in the egg-extract system.
In human cells, S387 of Rad9 (the
equivalent of S373 in Xrad9) is constitutively
phosphorylated during the cell cycle (29).
Therefore, phosphorylation of this residue does
not require the presence of DNA damage or stalled
DNA replication forks.  Consistent with this
observation, we have found that GST-Xrad9C can
associate with endogenous XtopBP1 in interphase
egg extracts even in the absence of a checkpoint-
inducing DNA template.  This type of apparently
constitutive process would allow the XtopBP1-
Xrad9 complex to function at a very early step in
the initiation of checkpoint signaling.  Since this
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7binding would not be dependent on regulation by
an upstream checkpoint-signaling kinase, this
complex could respond directly to checkpoint-
triggering signals in the genome.  Interestingly, the
sequences around S387 and S373 in human Rad9
and Xrad9, respectively, resemble the consensus
for phosphorylation by casein kinase 2 (CK2),
which is constitutively active throughout the cell
cycle (39).
The 9-1-1 complex is thought to recognize
recessed DNA ends that would abut regions of
single-stranded DNA at replication forks and sites
of damage (17-19,40).  Single-stranded DNA,
which would be coated with replication protein A,
attracts the binding of inactive ATR-ATRIP in
various systems (12,41,42).  Subsequently, Xatr-
Xatrip undergoes activation upon binding of
XtopBP1 (9,21,22).  Interaction of XtopBP1 with
the 9-1-1 complex may allow XtopBP1 to activate
Xatr-Xatrip when both recessed DNA ends and
single-stranded DNA are present (Fig. 7).
In principle, binding of the 9-1-1 complex
to XtopBP1 could be involved in the activation of
Xatr or the recognition of downstream substrates
by Xatr or both.  Our findings are most consistent
with a role for 9-1-1 in the events leading to the
formation of fully activated Xatr.  First, 9-1-1
interacts well with the established direct activator
of Xatr, namely XtopBP1.  Second, 9-1-1
associates with the region of XtopBP1 (i.e., BRCT
I-II) that is necessary for both binding and
activation of Xatr.  Finally, the isolated C-terminal
domain of Rad9 acts as a dominant-negative
inhibitor that blocks binding of Xatr to XtopBP1
and hence forestalls activation of Xatr.
It is possible that, in addition to localizing
XtopBP1 near Xatr-Xatrip, the 9-1-1 complex may
also trigger structural changes in XtopBP1 that
would allow interaction with Xatr-Xatrip.  We
suspect that XtopBP1 may exist in a repressed
form that would be incapable of activating Xatr
inappropriately in the absence of a checkpoint-
triggering signal.  Interaction of the BRCT I-II
region of XtopBP1 with the 9-1-1 complex on a
checkpoint-triggering DNA structure may alleviate
this repressed state.
The situation appears to be somewhat
different in budding yeast.  Majka et al. (43)
presented evidence that a recombinant version of
the 9-1-1 complex from this organism (Ddc1-
Mec3-Rad17) could activate Mec1-Ddc2 (ATR-
ATRIP) directly in vitro.  By contrast, the Xenopus
9-1-1 complex recruits XtopBP1, apparently the
most proximal activator of Xatr-Xatrip.
The exact roles of fission yeast Cut5 and
budding yeast Dpb11 in checkpoint activation are
not clear.  Since these proteins appear to lack an
obvious AAD, they may not interact with ATR in
the same manner as TopBP1.  However, Cut5 does
associate with Rad3 (ATR) in fission yeast during
checkpoint responses (30).  Interestingly, this
interaction requires phosphorylation of Rad9 on
T412.  Moreover, checkpoint-regulated
phosphorylation of both Cut5 and Crb2 is
dependent upon the T412 site in Rad9.  Thus, it
appears that Rad9 regulates Rad3-dependent
signaling in this system.  Further study of how
XtopBP1 and Cut5/Dpb11 respond to DNA
structures should provide additional insight into
the earliest steps in checkpoint-signaling
pathways.
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2The abbreviations used are:  ATM, ataxia-telangiectasia mutated; ATR, ATM and Rad3-related;
TopBP1, Topoisomerase IIβ binding protein 1; BRCT, BRCA1 carboxy-terminal; DSBs, double-stranded
DNA breaks.
FIGURE LEGENDS
FIGURE 1.  XtopBP1 associates with the C-terminal domain of Xrad9 in a phosphorylation-
dependent manner.  (A) Xenopus egg extracts (lanes 1, 3, and 4) and control buffer (lane 2) were
incubated in the absence (lane 1) or presence (lanes 2-4) of GST-Xrad9C.  Next, the samples were
incubated with glutathione agarose beads, and the beads were later retrieved and washed.  For lanes 3 and
4, the beads were incubated once more in the absence (lane 3) or presence (lane 4) of λ protein
phosphatase.  These beads were then washed again.  All samples were subjected to SDS-PAGE and
immunoblotted with anti-XtopBP1 and anti-GST antibodies.  Asterisk and arrow denote unshifted and
shifted forms of GST-Xrad9C, respectively.  (B) GST fusion proteins containing the indicated amino
acids of Xrad9 were subjected directly to SDS-PAGE (lanes 1, 3, 5, 7, and 9) or incubated in Xenopus egg
extracts (lanes 2, 4, 6, 8, and 10).  Subsequently, glutathione agarose beads were incubated in the egg
extracts, retrieved, and subjected to SDS-PAGE.  All samples were immunoblotted with anti-XtopBP1
and anti-GST antibodies.  (C) Sequence alignment of the C-terminal 40 amino acids of Xrad9 with the C-
terminal regions of human, mouse, and S. pombe Rad9.  Arrow indicates S373 of Xrad9.  Asterisks
denote T412 and S423 of S. pombe Rad9.  (D) The indicated versions of GST-Xrad9 were subjected to
SDS-PAGE directly (lanes 1, 3, and 5) or incubated in egg extracts and later retrieved with glutathione
beads (lanes 2, 4, and 6).  Samples were immunoblotted for XtopBP1 and GST.  (E) Wild-type and
S373A versions of GST-Xrad9C (residues 258-377) were incubated in egg extracts in the presence of [γ-
32P]ATP, isolated with glutathione agarose beads, and processed for tryptic phosphopeptide mapping as
described in “Experimental Procedures”.  The dotted circle demarcates the position of the S373-
containing peptide.  Origins are indicated by a dot.
FIGURE 2.  The S373A mutant of Xrad9 is compromised in checkpoint signaling.  (A) Baculoviruses
encoding His6-Xrad9, Xhus1, or Xrad1 were used to coinfect Sf9 insect cells.  The complexed
recombinant proteins were purified with nickel agarose beads.  Aliquots of preparations containing wild-
type (lane 2) or S373A mutant His6-Xrad9 (lane 3) were separated by SDS-PAGE and stained with
Coomassie Brilliant Blue dye.  Size markers were electrophoresed in lane 1.  Note that Xhus1 and Xrad1
have similar electrophoretic mobilities. (B) Egg extracts were mock-depleted with control antibodies (lane
1) or immunodepleted with anti-Xhus1 antibodies (lanes 2-4).  The extracts were later supplemented with
buffer alone (lanes 1 and 2), wild-type recombinant 9-1-1 complex (lane 3), or a mutant 9-1-1 complex
containing the Xrad9-S373A protein (lane 4).  Extracts were immunoblotted for Xhus1, Xrad9, and
XtopBP1.  (C) The indicated extracts from (B) were incubated with sperm chromatin and [35S]Xchk1 in
the absence (lane 1) or presence (lanes 2-5) of aphidicolin (APH).  Nuclear fractions were isolated,
subjected to SDS-PAGE, and processed for phosphorimaging to detect labeled Xchk1 (top) and for
immunoblotting with anti-Xrad9 and anti-Xhus1 antibodies (bottom).
FIGURE 3.  The BRCT I-II region of XtopBP1 is necessary and sufficient for binding of Xrad9.  (A)
Domain structure of XtopBP1.  (B) Xenopus egg extracts were incubated with buffer alone (lane 2) or the
indicated forms of XtopBP1 (lanes 3-9).  Beads containing anti-FLAG antibodies were added
subsequently.  The beads were later retrieved and processed for immunoblotting with antibodies against
the FLAG epitope, Xrad17, Xrad9, and Xhus1.  Lane 1 depicts an aliquot of the initial egg extract.  (C)
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Extracts were incubated with the indicated forms of HF-XtopBP1 in the presence (lanes 1 and 3-5) or
absence (lane 2) of GST-Xrad9C.  Glutathione agarose beads were added subsequently.  The beads were
retrieved and processed for immunoblotting with anti-FLAG antibodies.  (D) Egg extracts were incubated
with buffer alone (lanes 2 and 6) or fragments of XtopBP1 comprised of its N-terminal half (lane 3), C-
terminal half (lane 4), BRCT domains I-II (lane 7), or BRCT domains III-VI (lane 8).  Anti-FLAG
immunoprecipitates were immunoblotted for Xrad17, Xrad9, and Xhus1.  Lanes 1 and 5 depict aliquots of
initial egg extract.  (E) The indicated fragments of XtopBP1 were subjected to SDS-PAGE directly (lanes
1-4) or incubated in egg extracts (lanes 5-8).  Glutathione agarose beads were added subsequently to the
extracts.  The beads were later retrieved and processed for immunoblotting with anti-FLAG antibodies.
Arrows indicate the electrophoretic positions of the N-terminal (top) and BRCT I-II (bottom) fragments of
XtopBP1.
FIGURE 4.  The BRCT I-II region of XtopBP1 is essential for the phosphorylation of Xchk1.  (A)
Egg extracts were mock-depleted with control antibodies (lane 1) or immunodepleted with anti-XtopBP1
antibodies (lanes 2-5). Extracts were later supplemented with sperm chromatin and buffer alone (lanes 1
and 2), wild-type HF-XtopBP1 (lane 3), ΔAAD HF-XtopBP1 (lane 4), or ΔI-II HF-XtopBP1 (lane 5).
Extracts were immunoblotted for XtopBP1 and Xrad17.  (B) The indicated extracts from A were
incubated with [35S]Xchk1 in the absence (lane 1) or presence (lanes 2-5) of aphidicolin.  Nuclear
fractions from the extracts were subjected to SDS-PAGE and phosphorimaging.  (C) Mock-depleted
(lanes 1 and 2) and XtopBP1-depleted extracts (lanes 3-8) were supplemented with buffer alone (lanes 1-
4), wild-type HF-XtopBP1 (lanes 5 and 6), or ΔI-II HF-XtopBP1 (lanes 7 and 8).  The extracts were
incubated with [35S]Xchk1 in the presence of (dA)70 (lanes 1, 3, 5, and 7) or (dA)70-(dT)70 (lanes 2, 4, 6,
and 8).  Extracts were processed for phosphorimaging.
FIGURE 5. The BRCT I-II region of XtopBP1 is necessary for binding of Xatr-Xatrip.  (A) Egg
extracts (50 µl) were incubated with buffer alone (lanes 2 and 3), wild-type HF-XtopBP1 (lanes 4 and 5),
or ΔI-II HF-XtopBP1 (lanes 6 and 7) in the presence of (dA)70 (lanes 2, 4, and 6) or (dA)70-(dT)70 (lanes 3,
5, and 7).  Beads containing anti-FLAG antibodies were added subsequently.  Beads were retrieved and
processed for immunoblotting with anti-Xatr and anti-FLAG antibodies.  Lane 1 depicts the content of
Xatr in 1 µl of egg extract.  (B) Egg extracts containing added sperm chromatin and aphidicolin were
incubated with either wild-type HF-XtopBP1 (lanes 1 and 3) or ΔI-II HF-XtopBP1 (lanes 2 and 4).  After
60 min, nuclei were isolated by centrifugation through a sucrose cushion and solubilized as described in
“Experimental Procedures.”  Nuclear fractions were immunoprecipitated with anti-FLAG antibodies.
Solubilized nuclear fractions (lanes 1 and 2) and anti-FLAG immunoprecipitates from nuclear fractions
(lanes 3 and 4) were processed for immunoblotting with anti-FLAG and anti-Xatr antibodies.
FIGURE 6.  The GST-Xrad9 fragment containing residues 258-377 interferes with phosphorylation
of Xchk1.  (A) Egg extracts containing sperm chromatin were incubated with buffer alone (lanes 1 and 2),
wild-type GST-Xrad9C (lane 3), or S373A GST-Xrad9C (lane 4) in the absence (lane 1) or presence
(lanes 2-4) of aphidicolin.  Nuclear fractions were isolated and processed for immunoblotting with
antibodies against GST, phospho-S344 of Xchk1, Xchk1 protein, phospho-S864 of Claspin, Claspin
protein, and XtopBP1 as indicated.  (B) Egg extracts with added [35S]Xchk1 were incubated with buffer
alone (lanes 1 and 2), wild-type GST-Xrad9C (lane 3), or S373A GST-Xrad9C (lane 4) versions in the
absence (lane 1) or presence (lanes 2-4) of (dA)70-(dT)70.  Samples were subjected to SDS-PAGE and
phosphorimaging.  (C) Chromatin fractions from the indicated samples in (A) were immunoblotted for
bound XtopBP1, Xatr, and Xorc2.
FIGURE 7.  Model for interactions between the 9-1-1 complex, TopBP1, and ATR-ATRIP at stalled
replication forks.  See “Discussion” for details.
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